Literature DB >> 1911545

Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells.

M Kannagi1, S Harada, I Maruyama, H Inoko, H Igarashi, G Kuwashima, S Sato, M Morita, M Kidokoro, M Sugimoto.   

Abstract

We established long-term cell lines of cytotoxic T lymphocytes (CTL) specific for human T cell leukemia virus type I (HTLV-I) from peripheral blood lymphocytes (PBL) of a patient with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), an HTLV-I-carrier with Sjögren syndrome, and an asymptomatic HTLV-I-carrier, by repeated stimulation with autologous HTLV-I-infected T cells in vitro. CTL derived from the patient with HAM/TSP expressed CD8 antigen, and their function was restricted by HLA-A2. They showed cytotoxic effects predominantly against the target cells expressing HTLV-I p40tax among the autologous B cell lines infected with vaccinia recombinants containing various HTLV-I genes which served as targets. These data are consistent with the previously reported findings that fresh PBL of HAM/TSP patients contain p40tax-specific CTL activity. Furthermore, CTL derived from the patient with Sjögren syndrome without neurological involvement also demonstrated cytotoxicity predominantly to p40tax. The cytotoxicity to the target cells experimentally expressing p40tax was blocked by unlabeled HTLV-I-infected cells possessing HLA-A2. HTLV-I-specific cytotoxicity was also inhibited by unlabeled B cells bearing p40tax. Thus, HTLV-I p40tax-specific cytotoxicity is mediated by the major CTL population activated by native HTLV-I antigens in patients with HAM/TSP or Sjögren syndrome. In contrast to the CTL of these patients, CTL similarly induced from the asymptomatic HTLV-I-carrier, which were highly cytotoxic to autologous HTLV-I-infected T cells, did not show significant levels of cytotoxicity to autologous B cells expressing p40tax.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911545     DOI: 10.1093/intimm/3.8.761

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  102 in total

1.  Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade.

Authors:  S Hanabuchi; T Ohashi; Y Koya; H Kato; F Takemura; K Hirokawa; T Yoshiki; H Yagita; K Okumura; M Kannagi
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice.

Authors:  Paola Miyazato; Jun-ichirou Yasunaga; Yuko Taniguchi; Yoshio Koyanagi; Hiroaki Mitsuya; Masao Matsuoka
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia.

Authors:  Masakatsu Hishizawa; Kazunori Imada; Tomomi Sakai; Momoko Nishikori; Nobuyoshi Arima; Mitsuru Tsudo; Takayuki Ishikawa; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

4.  DC-SIGN facilitates fusion of dendritic cells with human T-cell leukemia virus type 1-infected cells.

Authors:  Pierre-Emmanuel Ceccaldi; Frédéric Delebecque; Marie-Christine Prevost; Arnaud Moris; Jean-Pierre Abastado; Antoine Gessain; Olivier Schwartz; Simona Ozden
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax301-309-Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients.

Authors:  Yuko Ishihara; Yukie Tanaka; Seiichiro Kobayashi; Koji Kawamura; Hideki Nakasone; Ayumi Gomyo; Jin Hayakawa; Masaharu Tamaki; Yu Akahoshi; Naonori Harada; Machiko Kusuda; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Kana Sakamoto; Miki Sato; Kiriko Terasako-Saito; Misato Kikuchi; Shun-Ichi Kimura; Aki Tanihara; Shinichi Kako; Kaoru Uchimaru; Yoshinobu Kanda
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 6.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 7.  Leukemogenesis of adult T-cell leukemia.

Authors:  Jun-ichirou Yasunaga; Masao Matsuoka
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients.

Authors:  K Furukawa; M Mori; N Ohta; H Ikeda; H Shida; K Furukawa; H Shiku
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

Review 9.  Immunologic control of human T-cell leukemia virus type I and adult T-cell leukemia.

Authors:  Mari Kannagi
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

Review 10.  Implication of the HTLV-I bZIP factor gene in the leukemogenesis of adult T-cell leukemia.

Authors:  Yorifumi Satou; Masao Matsuoka
Journal:  Int J Hematol       Date:  2007-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.